怡和嘉業(301367.SZ):與翰宇藥業、翰宇健康簽署戰略合作框架協議
格隆匯5月12日丨怡和嘉業(301367.SZ)公佈,爲充分發揮各方在睡眠健康領域的協同優勢,北京怡和嘉業醫療科技股份有限公司與深圳翰宇藥業股份有限公司(簡稱“翰宇藥業”)、深圳翰宇健康科技有限公司(簡稱“翰宇健康”)於2025年5月12日共同簽署了《戰略合作框架協議》。基於三方在技術研發、產品創新及渠道資源等方面的互補性,本次合作旨在整合優勢資源,構建“產品+器械”協同發展的睡眠健康生態系統,共同探索睡眠障礙預防、治療及健康管理的創新模式。通過聯合品牌推廣及市場拓展,實現互利共贏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.